related substances comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-23. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
=== Colon Treaty of Peace and Friendship === On August 26, 1876, the Grand Lodge of Colon in Santiago de Cuba declared itself entirely independent as a sovereign Masonic Body with its own full and unlimited powers over its own subordinate lodges. Under their auspices, the Grand Lodge of Colon possessed 36 lodges and 8,000 members. On November 24, 1876, the Grand Lodge of Colon and the Supreme Council of Colon signed the Tratado de Paz y Amistad (English: Treaty of Peace and Friendship). This treaty was based in the agreements of the Lausanne Congress. It degraded the superior prestige of the higher degrees, eliminated authoritarian positions at the Supreme Council, ejected the Spanish aristocracy from holding undue power, and erased the mystical positions. The Supreme Council of Colon recognized the Grand Lodge of Colon as "regular and correct," and also recognized their authority over the three degrees of the Blue Lodge. The Grand Lodge recognized the Supreme Council as the authority over the 4th to 33rd degrees.
=== Blood group systems === Red blood cell membranes consist of a phospholipid bilayer, littered with proteins, lipids, carbohydrates, and combinations of these substances. These substances are called antigens because they stimulate an immune response when an individual is exposed to the substance, but the exposed individual does not carry nor express the genes which encode said antigens. Each individual has a unique genetic and phenotypic makeup of antigens, much like the dermatoglyphics of human fingerprints. As of 2023, there are 44 blood group systems, each containing several red blood cell antigens totaling 354, determined by approximately 49 separate genes. Of these antigens, only a handful are considered clinically significant, meaning that they can stimulate the production of antibodies capable of causing red cell hemolysis. This is particularly important for the transfusion of packed red blood cells and other cellular blood products. Examples of blood group systems that contain antigens capable of inducing clinically significant alloantibodies (antibodies against non-self antigens) include, but are not limited to the ABO, Rh, Kell, Duffy, Kidd, and MNS blood group systems.
== External links == David S, Lancaster T, Stead LF. Opioid antagonists for smoking cessation (Cochrane Review), The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. Opioid+Antagonists at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
Phenoloxidase system is a major defense system in many invertebrates which ultimately leads to melanization of pathogens and damaged tissues. The process of melanization depends on activation of the enzyme phenoloxidase (PO) which is controlled by the prophenoloxidase (proPO) activation system. During activation of the proPO cascade, many other immune reactions are produced, such as cytotoxic, opsonic and encapsulation activities. The phenoxidase cascade plays an important role in invertebrates (especially insects) in three physiologically important processes: immune reactions, sclerotization of the cuticle and wound healing.
0.063 in or 1.6 mm 0.058 in or 1.5 mm 0.050 in or 1.3 mm 0.043 in or 1.1 mm The end of the saw power head has two oil holes, one on each side. These holes must match with the outlet of the oil pump. The pump sends the oil through the hole in the lower part of the gauge. Saw bar producers provide a large variety of bars matching different saws. Grease is pumped through a hole at the bar nose, typically each tank filling to keep the nose sprocket well lubricated. One or two bolts from the saw run through a guide slot. The clutch cover is put on top of the bar and it is secured through these bolts. The number of bolts is determined by the size of the saw. Different bar types are available:
Legal expert Julien Jeanneney argued that the "unconstitutional" policies of Trump are backed by the Supreme Court, of which a third of the judges had been appointed by Trump during his first presidency, hence making Republican judges the majority. According to Jeanneney most of the judges "seem clearly on Trump's side concerning most of his policies, even when they violate the Court's long-lived principles". Numerous experts of fascism and historians (Jason Stanley, Marci Shore, Timothy Snyder, Johann Chapoutot, Paul Lerner, Anne Berg, Diana Garvin, Tiffany Florvil, Claudia Koonz, Asma Mhalla, and Ben Worthy) denounced the authoritarianism of the presidency, which they explicitly linked to fascism. However experts Christopher R. Browning, Roger Griffin, Janos Bourgeois, Lloyd Cox and Brendon O'Connor contested this comparison, although Browning noted "uncanny resemblances" between Trump and Hitler, and Cox and O'Connor talked about "proto-fascist phenomenon".
=== Resolution === The inflammatory response must be actively terminated when no longer needed to prevent unnecessary "bystander" damage to tissues. Failure to do so results in chronic inflammation, and cellular destruction. Resolution of inflammation occurs by different mechanisms in different tissues. Mechanisms that serve to terminate inflammation include:
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.